OMOM CC Colon Capsule
OMOM CC provides non-invasive colorectal visualization through a dual-lens capsule design with 344-degree combined field of view. The system targets patients who decline traditional colonoscopy or require examination following incomplete prior procedures.
Product Overview
Colorectal cancer screening remains a significant public health challenge due to patient reluctance toward invasive colonoscopy. OMOM CC addresses this barrier by offering a swallowable alternative that captures full colonic imagery without sedation, intubation, or the discomfort associated with conventional endoscopy.
Multi-center European studies have evaluated real-world performance of the OMOM CC platform, with results presented at World Congress of Gastroenterology (WCOG) and United European Gastroenterology (UEG) Week demonstrating clinical feasibility as a patient-friendly diagnostic option.
Key Features
CE-marked and NMPA-approved, OMOM CC’s dual-lens capsule combines a 344-degree field of view with a 15-hour battery and Vue Smart AI for colorectal polyp screening.
- Dual-Lens Design: Front and rear cameras provide 344-degree combined field of view for full mucosal coverage
- Intelligent Variable Frame Rate: 4-35 FPS adaptive capture adjusts to capsule transit speed
- Extended Battery Life: 15 hours ensures complete colonic transit in most patients
- AI-Powered Analysis: Vue Smart software integration for automated polyp detection and size estimation
- Patient-Friendly: No sedation, no intubation, minimal procedural discomfort
Technical Specifications
CE-marked for European distribution, the OMOM CC dual-lens capsule uses 4–35 fps adaptive capture to achieve 344-degree colonic mucosal coverage over a 15-hour battery life.
| Parameter | Specification |
|---|---|
| Capsule Configuration | Dual-lens (front + rear) |
| Combined Field of View | 344 degrees |
| Frame Rate | 4-35 FPS (intelligent variable) |
| Battery Life | 15 hours |
| Image Quality | High-definition |
| AI Integration | Vue Smart platform |
Clinical Applications
OMOM CC is positioned as a screening tool for colorectal pathology in specific patient populations:
Primary Indications:
- Patients declining conventional colonoscopy
- Completion imaging after technically incomplete colonoscopy
- Surveillance in patients with contraindications to sedation
- Initial screening in average-risk populations seeking non-invasive options
Limitations:
- No therapeutic capability (biopsy, polypectomy not possible)
- Positive findings require follow-up colonoscopy
- Bowel preparation still required
Regulatory Status
| Region | Status | Date |
|---|---|---|
| China (NMPA) | Approved | Yes |
| Europe (CE Mark) | Approved | Yes |
| United States (FDA) | Not Cleared | - |
European market access enables distribution in EU member states, with ongoing clinical studies supporting expanded adoption.
Frequently Asked Questions
Can OMOM CC replace colonoscopy?
OMOM CC serves as a screening tool that may identify patients requiring therapeutic colonoscopy. It does not replace colonoscopy for patients with positive findings, as tissue sampling and polyp removal require conventional endoscopic access.
What bowel preparation is needed for OMOM CC?
Similar to colonoscopy, effective colon capsule endoscopy requires thorough bowel cleansing. Patients follow a clear liquid diet and consume bowel preparation solution to ensure adequate visualization of colonic mucosa.
How accurate is OMOM CC for polyp detection?
Clinical studies of colon capsule technology demonstrate detection rates of 84-88% for polyps larger than 6mm, with higher sensitivity for larger lesions. Per-patient sensitivity for clinically significant lesions exceeds 80% in published literature.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.